1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY BLOCKCHAIN TYPE
5.1. Introduction
5.2. Private
5.3. Public
5.4. Consortium
5.5. Hybrid
6. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY APPLICATION
6.1. Introduction
6.2. Patient Data Management
6.3. Clinical Data Exchange & Sharing
6.4. Drug Tracebility & Authenticity
6.5. Smart Contracts
6.6. Others
7. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY END-USER
7.1. Introduction
7.2. Pharmaceutical & Biotech Companies
7.3. Research & Academic Institutes
7.4. Others
8. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Italy
8.4.6. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Taiwan
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. IBM
10.2. Microsoft Corporation
10.3. Oracle Corporation
10.4. Accenture PLC
10.5. Consensys Health
10.6. Bitfury Group Limited
10.7. FarmaTrust
10.8. LabTrace
10.9. Chronicled
10.10. iSolve
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES